Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic Complications

New England Journal of Medicine

Volumn 318, Issue 20, 1988, Pages 1315-1321

  Flier, Jeffrey S ^a   Underhill, Lisa H ^a   Brownlee, Michael ^b   Cerami, Anthony ^b   Vlassara, Helen ^b  

^a Laboratory of Medical Biochemistry ^*

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS; GLYCOSYLATION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

ANIMAL; DIABETES MELLITUS; GLYCOSYLATION; HUMAN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023950461     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198805193182007     Document Type: Review

References (59)

1. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984; 101: 527–37.
2. Brownlee M, Vlassara H, Cerami A. The pathogenic role of nonenzymatic glycosylation in diabetic complications. In: Crabbe MJC, ed. Diabetic complications: scientific and clinical aspects. London: Churchill Livingstone, 1987:94–139.
3. Brownlee M, Cahill GF Jr. Diabetic control and vascular complications. In: Paoletti R, Gotto AM, eds. Atherosclerosis reviews. Vol. 4. New York: Raven Press, 1979:29–70.
4. Brownlee M, Cerami A. The biochemistry of the complications of diabetes mellitus. Annu Rev Biochem 1981; 50: 385–432.
5. Alberti KGMM, Press CM. The biochemistry of the complications of diabetes mellitus. In: Keen H, Jarrett J, eds. Complications of diabetes. 2nd ed. London: Edward Arnold, 1982:231–70.
6. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375–80.
7. Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides, and sodium–potassium–ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316: 599–606.
8. Winegrad AI. Does a common mechanism induce the diverse complications of diabetes? Diabetes 1987; 36: 396–406.
9. Bresnick GH. Diabetic retinopathy. In: Peyman GA, Sanders DR, Goldberg MF, eds. Principles and practice of ophthalmology. Philadelphia: W.B. Saunders, 1980:1205–76.
10. Kohner EM, McLeod D, Marshall J. Diabetic eye disease. In: Keen H, Jarrett J, eds. Complications of diabetes. 2nd ed. London: Edward Arnold, 1982:19–108.
11. Ashton N. Pathogenesis of diabetic retinopathy. In: Little HL, Jack RL, Patz A, Forsham PH, eds. Diabetic retinopathy. New York: Thieme-Stratton, 1983:86–106.
12. The kidney in diabetes: Symposium, Steno Memorial Hospital, Copenhagen, September 1980. Acta Endocrinol [Suppl] (Copenh) 1981; 242: 1–64.
13. Mogensen CE, Steffes MW, Deckert T, Christiansen JS. Functional and morphological renal manifestations in diabetes mellitus. Diabetologia 1981; 21: 89–93.
14. Mogensen CE. Diabetes mellitus and the kidney. Kidney Int 1982; 21: 673–9.
15. Mauer SM, Steffes MW, Goetz FC, et al. Diabetic nephropathy: a perspective. Diabetes 1983; 32: Suppl 2: 52–5.
16. Wallow IHL, Engerman RL. Permeability and patency of retinal blood vessels in experimental diabetes. Invest Ophthalmol Vis Sci 1977; 16: 447–61.
17. Porta M, Townsend C, Clover GM, et al. Evidence for functional endothelial cell damage in early diabetic retinopathy. Diabetologia 1981; 20: 597–601.
18. Viberti GC, Bilous RW, Mackintosh D, Bending JJ, Keen H. Long term correction of hyperglycaemia and progression of renal failure in insulin independent diabetes. Br Med J 1983; 286: 598–602.
19. Shimomura H, Spiro RG. Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes: decreased levels of heparan sulfate proteoglycan and laminin. Diabetes 1987; 36: 374–81.
20. Shemesh O, Jones HW, Myers BD. Pathophysiology of proteinuria in diabetic neuropathy. In: Robinson RR, ed. Proceedings of the Ninth International Congress of Nephrology. Vol. 2. New York: Springer-Verlag, 1984:1081–93.
21. Tomlanovich S, Deen WM, Jones HW III, Schwartz HC, Myers BD. Functional nature of glomerular injury in progressive diabetic glomerulopathy. Diabetes 1987; 36: 556–65.
22. Steffes MW, Buchwald H, Wigness BD, et al. Diabetic nephropathy in the uninephrectomized dog: microscopic lesions after one year. Kidney Int 1982; 21: 721–4.
23. Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 1985; 82: 5963–7.
24. Osterby R, Gundersen HJG, Nyberg G, Aurell M. Advanced diabetic glomerulopathy: quantitative structural characterization of nonoccluded glomeruli. Diabetes 1987; 36: 612–9.
25. Glaser BM, D'Amore PA, Michels RG, Patz A, Fenselau A. Demonstration of vasoproliferative activity from mammalian retina. J Cell Biol 1980; 84: 298–304.
26. Glaser BM, Patz A. Neovascularization: current concepts. In: Little HL, Jack RL, Patz A, Forsham PH, eds. Diabetic retinopathy. New York: Thieme-Stratton, 1983:367–90.
27. King GL, Goodman AD, Buzney S, Moses A, Kahn CR. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 1985; 75: 1028–36.
28. Ross R. The pathogenesis of atherosclerosis — an update. N Engl J Med 1986; 314: 488–500.
29. Vishwanath V, Frank KE, Elmets CA, Dauchot PJ, Monnier VM. Glycation of skin collagen in type I diabetes mellitus: correlation with long-term complications. Diabetes 1986; 35: 916–21.
30. Brownlee M, Pongor S, Cerami A. Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen: role in the in situ formation of immune complexes. J Exp Med 1983; 158: 1739–44.
31. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 1985; 34: 938–41.
32. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629–32.
33. Eble AS, Thorpe SR, Baynes JW. Nonenzymatic glucosylation and glucose-dependent cross-linking of protein. J Biol Chem 1983; 258: 9406–12.
34. Kent MJC, Light ND, Bailey AJ. Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation in vitro. Biochem J 1985; 225: 745–52.
35. Farmar JG, Ulrich PC, Cerami A. Sulfite trapping of nonenzymatic browning intermediates. J Organ Chem (in press).
36. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 1984; 81: 583–7.
37. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of Type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986; 314: 403–8.
38. Stender S, Hjelms E. In vivo influx of free and esterified plasma cholesterol into human aortic tissue without atherosclerotic lesions. J Clin Invest 1984; 74: 1871–81.
39. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Inhibition of diabetes-induced arterial wall lipoprotein deposition and prevention of arterial wall collagen crosslinking by aminoguanidine. Diabetologia 1986; 29: 523a. abstract.
40. Sensi M, Tanzi P, Bruno MR, Mancuso M, Andreani D. Human glomerular basement membrane: altered binding characteristics following in vitro non-enzymatic glycosylation. Ann NY Acad Sci 1986; 488: 549–52.
41. Brownlee M, Vlassara H, Kooney A, Cerami A. Inhibition of glucose-derived protein crosslinking and prevention of early diabetic changes in glomerular basement membrane by aminoguanidine. Diabetes 1986; 35: Suppl: 42A. abstract.
42. Monnier VM, Cerami A. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 1981; 211: 491–3.
43. Miller EJ, Gay S. Collagen: an overview. In: Colowick S, Cunningham LW, eds. Methods in enzymology. Vol. 82. Cunningham LW, Frederiksen DW, eds. Structural and contractile proteins. Part A. Extracellular matrix. New York: Academic Press, 1982:3–32.
44. Miller EJ, Rhodes RK. Preparation and characterization of the different types of collagen. In: Colowick S, Cunningham LW, eds. Methods in enzymology. Vol. 82. Cunningham LW, Frederiksen DW, eds. Structural and contractile protein. Part A. Extracellular matrix. New York: Academic Press, 1982:33–52.
45. Yurchenco PD, Tsilibary EC, Charonis AS, Furthmayr H. Models for the self-assembly of basement membrane. J Histochem Cytochem 1986; 34: 93–102.
46. Tsilibary EC, Charonis AS, Furcht LT. Changes of the main non-collagenous NCI domain of type IV collagen after in vitro non-enzymatic glucosylation. Diabetes 1987; 36: Suppl 1: 85A. abstract.
47. Vlassara H, Brownlee M, Cerami A. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J Exp Med 1986; 164: 1301–9.
48. Vlassara High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 1985; 82: 5588–92.
49. Radoff S, Vlassara H, Cerami A. Isolation of a macrophage receptor for proteins modified by advanced glycosylation endproducts (AGE). Fed Proc 1987; 46: 2116. abstract.
50. Vlassara H, Brownlee M, Cerami A. Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo. Diabetes 1988; 37: 456–61.
51. Vlassara H, Brownlee M, Manogue K, Pasagian A, Cerami A. Cachectin/TNF and IL-2 synthesis and secretion are induced by glucose-modified protein binding to a high affinity macrophage receptor. Science (in press).
52. Le J, Vilček J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 1987; 56: 234–48.
53. Daniel TO, Gibbs VC, Milfay DF, Garovay MR, Williams LT. Thrombin stimulates c-sis gene expression in microvascular endothelial cells. J Biol Chem 1986; 261: 9579–82.
54. Stolpen AH, Guinan EC, Fiers W, Pober JS. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am J Pathol 1986; 123: 16–24.
55. Rosenbaum JT, Samples JR, Howes EL Jr. Tumor necrosis factor induces neovascularization and sustained vascular permeability in the rabbit eye. Fed Proc 1987; 46: 788. abstract.
56. Klein DJ, Brown DM, Oegema TR. Glomerular proteoglycans in diabetes: partial structural characterization and metabolism of de novo synthesized heparan-35SO4 and dermatan-35SO4 proteoglycans in streptozocin-induced diabetic rats. Diabetes 1986; 35: 1130–42.
57. Brownlee M, Vlassara H, Cerami A. Aminoguanidine prevents hyperglycemia-induced defect in binding of heparin by matrix molecules. Diabetes 1987; 36: Suppl 1: 85A. abstract.
58. Le Pape A, Gutman N, Guitton JD, Legrand Y, Muh JP. Non enzymatic glycosylation increases platelet aggregating potency of collagen from placenta of diabetic human beings. Biochem Biophys Res Commun 1983; 111: 602–10.
59. Cerami A, Vlassara H, Brownlee M. Glucose and aging. Sci Am 1987; 256(5):90–6.